AN ASSESSMENT OF THE PRIMARY PREVENTION CONTROL PROGRAM OF PHC PREVENTIVE CARDIOLOGY CLINIC AMONG PATIENTS AT RISK FOR CVD: A Retrospective Cohort Study.

Slides:



Advertisements
Similar presentations
Definitions Body Mass Index (BMI) describes relative weight for height: weight (kg)/height (m 2 ) Overweight = 25–29.9 BMI Obesity = >30 BMI.
Advertisements

Cardio-Metabolic Syndrome Guidelines on Education, Detection and Early Treatment  Heval Mohamed Kelli, PGY-2 Emory Internal Medicine Residency no conflict.
U.S. Dept of Health and Human Services. National High Blood Pressure Education Program. Seventh Report of Joint National Committee on Prevention, Detection,
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Bridget Dillon February 11,  Cardiovascular disease affects the heart and circulatory system. It is often a result of blockages of blood vessels.
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care
N=1.831n=3.739n=3.374n=15.904n=13.297n=2.081 BP stratification according with 2003 ESH/ESC guidelines in Italian hypertensive patients included in population.
Special Diabetes Program for Indians Competitive Grant Program SPECIAL DIABETES PROGRAM FOR INDIANS Competitive Grant Program Clinical Goals for the Healthy.
Overview of the CVD Risk Reduction Demonstration Project Kelly Acton, MD, MPH, FACP IHS Division of Diabetes Treatment & Prevention.
CVD Risk Factor Reduction Kelly Moore, MD, FAAP IHS Division of Diabetes Treatment & Prevention.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
E NHANCING C OMPREHENSIVE HIV C ARE : Addressing Cardiovascular Disease (CVD) and other Noncommunicable Diseases (NCDs) Kwasi Torpey MD PhD MPH FGCP Deputy.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
Cardiovascular Disease in Women Module III: Risk Assessment Tool.
Health Disparities in Cardiovascular Disease Paula A. Johnson, MD, MPH Chief, Division of Women’s Health; Executive Director, Connors Center for Women’s.
Tt HRB Centre for Health and Diet Research The burden of hypertension Ivan J Perry, Dept. of Epidemiology and Public Health, University College Cork. Institute.
Establishing Preventive Cardiology Programs Nathan Wong Nathan Wong.
{ A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting Guideline-Based CPRS Dialog Adam Simons MD.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
Global impact of ischemic heart disease World Heart Federation, 2011.
Clinical experience with ezetimibe/simvastatin in a Mediterranean population The SETTLE Study I. Migdalis a, A. Efthimiadis b, St. Pappas c, D. Alexopoulos.
Nutrition and Cardiovascular Disease. Cardiovascular Disease Includes heart attack, stroke Includes heart attack, stroke Leading cause of death in the.
1FHI 360 Nigeria. 2USAID Nigeria
William B. Kannel, MD, FACC Former Director, Framingham Heart Study
The effects of initial and subsequent adiposity status on diabetes mellitus Speaker: Qingtao Meng. MD West China hospital, Chendu, China.
Cardiovascular Health and Risk Reduction in Children and Adolescents
Hypertension the Community - Overview HYPERTENSION IN THE COMMUNITY: OVERVIEW.
Effect of Hypertension and Dyslipidemia on glycemic control among Type 2 Diabetes patients in Thailand Dr. Mya Thandar Dr.PH. Batch 5 1.
Epidemiology of CVD in the Elderly Karen P. Alexander MD Duke University Medical Center Duke Clinical Research Institute Disclosures: (1) Minor Research:
Metabolic Syndrome Yusra Mir, MD Zunairah Syed, MD Harjagjit Maan, MD.
1. Relation between dietary macronutrient and fiber intake with metabolic syndrome in Tehranian adults: Tehran Lipid and Glucose Study Hosseinpour S,
Healthy Heart Initiative and the Role of the Pharmacist Alexis Beyer, PharmD, NCPS Cherokee Indian Hospital Healthy Heart Pharmacist.
The TRial Of Preventing HYpertension (TROPHY) TROPHY.
Prof K Srinath Reddy President Public Health Foundation of India & Professor of Cardiology All India Institute of Medical Sciences, New Delhi Prof K Srinath.
Effect of Hypertension and Dyslipidemia on glycemic control among Type 2 Diabetes patients Dr. Mya Thandar.
Dyslipidemia.  Dyslipidemia is elevation of plasma cholesterol, triglycerides (TGs), or both, or a low high- density lipoprotein level that contributes.
* Indicates p < 0.05 indicates p < 0.05 Evaluating Clinical Pharmacist Impact on Diabetes Control* Mary Ella Hill, Pharm. D. Candidate; Orijane Dalton,
Critical Appraisal Did the study address a clearly focused question? Did the study address a clearly focused question? Was the assignment of patients.
中国农村心血管病防治面临的挑战 Challenges in prevention and control of CVD in Rural China Yangfeng Wu, MD, PhD The George Institute for Global Health at Peking University.
Cardiovascular Disease Healthy Kansans 2010 Steering Committee Meeting April 22, 2005.
Effect of Hypertension and Dyslipidemia on glycemic control among Type 2 Diabetes patients in Thailand Dr. Mya Thandar DrPH Batch 5 1.
AA-2-1 Jerome D. Cohen, MD, FACC, FACP Professor of Internal Medicine / Cardiology Director, Preventive Cardiology Programs St. Louis University Health.
Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.
CVD Epidemiology Case Studies Nathan D. Wong PhD, FACC, Associate Professor and Director, Heart Disease Prevention Program, University of California, Irvine.
Risk Factor Modification in CCR. How does CR work?
Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients Gradman AH, Parisé H, Lefebvre P, Falvey H, Lafeuille MH,
Ross T. Tsuyuki, BSc(Pharm), PharmD, MSc, FCSHP, FACC Yazid NJ Al Hamarneh, BPharm, PhD Charlotte Jones, MD, PhD, FRCP(C) Brenda Hemmelgarn, MD, PhD, FRCP(C)
Dr. Nadira Mehriban. INTRODUCTION Diabetic retinopathy (DR) is one of the major micro vascular complications of diabetes and most significant cause of.
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease (HOPE-3 trial) R4. 박은지 / PF. 정혜문 Salim Yusuf, M.B., B.S., D.Phil.,
DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Effectiveness of Pharmacist Interventions on.
Case 1: Elevated LDL-C in a Young Adult. Page 2 of 10 *DALY; disability-adjusted life years Routine checkup:  Age:33 years  Sex: male  Status: Except.
Presented by Slyter Nutrition Consulting Services.
prevention and control of non communicable diseases in Iraq
Cholesterol practice questions
The Anglo Scandinavian Cardiac Outcomes Trial
First time a CETP inhibitor shows reduction of serious CV events
Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults Risks and Assessment NHLBI Obesity Education.
Prevention Cardiovascular disease
An Endocrinology Clinic in Dyslipidemia
Systolic Blood Pressure Intervention Trial (SPRINT)
Baseline characteristics of HPS participants by prior diabetes
Rational Order of Laboratory Tests in Cardiovascular Diseases
Lipid-Lowering Arm (ASCOT-LLA): Results in the Subgroup of Patients with Diabetes Peter S. Sever, Bjorn Dahlöf, Neil Poulter, Hans Wedel, for the.
Goals & Guidelines A summary of international guidelines for CHD
Cardiovascular Disease in Women Module III: Risk Assessment Tool
Section 6: Update on lipid treatment guidelines
Presentation transcript:

AN ASSESSMENT OF THE PRIMARY PREVENTION CONTROL PROGRAM OF PHC PREVENTIVE CARDIOLOGY CLINIC AMONG PATIENTS AT RISK FOR CVD: A Retrospective Cohort Study Preventive Cardiology Division, Philippine Heart Center

INTRODUCTION According to Global Burden of Disease Study estimate, CVD accounted for 10% of global disease burden, with a projected rise to almost 15% by Cardiovascular disease is the single most common cause of death in the world. Risk factor management should be thought of as prevention or treatment of the atherosclerotic disease process itself and, as such, should be included as an integral part of any management plan for the many acute or chronic manifestations of this disease.

PREVALENCE OF RISK FACTORS % Dans A. et al National Nutrition and Health Survey (NNHeS): Atherosclerosis-related Diseases and Risk Factors and 2008

OBEJCTIVES General Objective: –Evaluate effectiveness of the primary prevention control program for CVD of the Preventive Cardiology Division of the Philippine Heart Center. Specific Objectives: –Determine the mean change of the SBP, DBP, FBS and lipid profile from baseline and on follow-up. –Determine the percentage of patients who eventually developed CVD.

METHODOLOGY Trial Design –Retrospective cohort trial. Inclusion Citeria –Adults > 21 years old –Any one of the major risk factors. –Any one of the predisposing risk factors but with at least 1 major risk factor. –Patients with a minimum follow-up period of 3 consecutive years and at least 2 follow-ups per year will be included in the efficacy analysis of the study. Exclusion Criteria –Patients are considered ineligible to participate if they have an existing atherosclerotic cardiovascular disease (e.g. CAD, CVA, etc.) MAJOR RISK FACTORS Hypertension Diabetes mellitus Dyslipidemia PREDISPOSING RISK FACTORS Obesity Physical inactivity Family history of premature CHD

INTERVENTION Health Education Nutrition Counseling Exercise Prescription Guideline for the management of individual risk factors provided by the following: –NCEP-ATP III –JNC VII –ADA’s Standards of Diabetes Care

Data Management Data for all enrolled patients were captured in an initial evaluation form and the follow-up data were written on the follow-up forms. The data were encoded in a computerized database designed specifically for the clinical trial by trained data encoder.

Data Analysis The distribution of the baseline characteristics were described. The BP, FBS, lipid profile for all visits were plotted in a graph. The mean change from baseline and on follow- up for the BP, FBS, and lipid profile were estimated at 95% confidence level. The percentage of patients who developed CVD during the follow-up period were determined.

RESULTS From February 2002 to December 2009, there were a total of 1008 patients who are actively following up at our clinic. Out of the 1008 patients being seen at our clinic, 148 patients, satisfied the inclusion criteria for assessment of efficacy of treatment intervention.

RESULTS N = 1008 patients Sex: Age:

RESULTS N = 148 patients

BP on follow-up BP reduction from baseline of 11/20 mmHg (p< 0.05)

FBS on follow-up FBS mean reduction of 51 mg/dL from baseline (p = 0.79).

Lipid Profile on follow-up TC mean reduction = 24mg/dl (p=0.49); TG mean reduction = 55mg/dl (p=0.002); HDL mean reduction = 1mg/dl (p=ns); LDL mean reduction = 11mg/dl (p=ns)

RESULTS During the seven years follow-up: –six patients (4 males and 2 females) died due to cardiovascular disease –three (2 males and 1 female) died from other causes One female patient had myocardial infarction. Two males had cerebrovascular accident.

Conclusions The results of our intervention on our patients enrolled in the Primary Prevention Clinic showed a reduction in the CV risk factors. Though the BP reduction was significant, the target blood pressure set by the guidelines was not achieved. There were reductions in the FBS, TC and LDL- C but was not statistically significant. There was a significant decrease in TG and a non-significant small decrease in HDL-C.

Recommendations Strengthening of the health education programs, including the nutrition counseling, should be done. Exercise programs that will address the concern on obesity should be strengthened. Intervention programs to help stop smoking should also be initiated.

An ounce of prevention is better than a pound of cure. Thank you!